Introduction: Beta+R346K and Mu+K417N share the same haplotype with R346K, K417N, E484K and N501Y mutations in the receptor-binding domain (RBD) in the spike protein, as shown in Figure 2.
Introduction: In late September, the Alpha variant (B.1.1.7) harboring the N501Y mutation that conferred higher infectivity emerged in the UK and spread rapidly all over the world before vaccines became widely available in December.
Discussion: reported that neutralization efficacy was reduced for the Mu variant harboring R346K, E484K and N501Y in the PMID: 35367284
2022
Virus research
Table: N501Y
Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage.
Result: The spike protein substitutions observed in C.1.2 include five within the N-terminal domain (NTD: C136F, Y144del, R190S, D215G, and 242-243del or 2
Result: The majority of these substitutions (P9L, C136F, R190S, D215G, L242del, A243del, Y449H, E484K, N501Y, H655Y, and T716I), however, appeared simultaneously, further supporting a single, prolonged infection giving rise to this lineage.
Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination.
Result: An additional five mutations had <= 2-fold increased binding to human ACE2 (Figure 2C-D): L452R (in B.1.427/429 and B.1.617), Y453F (in B.1.1.298), E484Q (in B.1.617.1 and B.1.617.3) and N501Y (in B.1.1.529, B.1.1.7, B.1.351 and P.1).
Result: Notably, structural analyses show that 5 escape mutations (K417N/E484K/N501Y, G446V, F456E, N487R, F490L) are located within the interface of RBD-ACE2 interaction, indicating that this RBD subdomain is important in neutralizing SARS-CoV-2 infection.
Result: The most prevalen
Dynamic Ca(2+) sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry.
Result: This could be due to enhanced binding of RBD of B.1.1.7 with ACE2 due to N501Y mutation, which enhances receptor recognition and fusion, or simply due to enhanced triggering, consistent with previous data.
The basis of mink susceptibility to SARS-CoV-2 infection.
Introduction: In the mouse model, the N501Y mutation has been associated with increased infectivity and virulence of SARS-CoV-2 (Gu et al.).
Introduction: Nowadays, the N501Y mutation characterizes the novel SARS-CoV-2 variant from the UK named VOC202012/01 (B.1.1.7) (European Centre for Disease Prevention and Control), which was recently detected in Poland (Hryhorowicz et al.).
Introduction: Some of these mutations, such as the 69-70 deletion in combination with the N501Y variant, increase the transmissibility of SARS-CoV-2.
Introduction: The RBD included 44 mutation sites, in which the S77N, V483A, A344S, and N501Y mutations were the most frequent, while the Y453, G476, F486, T500, and N501 mu
SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges.
PMID: 35377298
2022
The Journal of general virology
Abstract: All four VOCs were able to overcome a previous restriction for mouse ACE2, with demonstrable differences also seen for individual VOCs with rat, ferret or civet ACE2 receptors, changes that we subsequently attributed to N501Y and E484K substitutions within the spike RBD.
CRISPR-Cas13a cascade-based viral RNA assay for detecting SARS-CoV-2 and its mutations in clinical samples.
PMID: 35370361
2022
Sensors and actuators. B, Chemical
Result: 5, A), to test their capability of distinguishing the N501Y mutant from the wild type.
Result: Spike glycoprotein mutations, such as the N501Y mutation, are present in many SARS-CoV-2 variants.
Result: Then, we sought to determine if the Cas13C assay had the ability to discriminate N501Y mutations in the presence of varying proportions of wild type RNAs.
Result: We found that the Cas13C assay was able to discriminate the N501Y-mutated variant when it was
Figure: (A) Design of crRNA_S (1-5) for identifying N501Y mutations.
Figure: (C) The Cas13C assay can detect the mutant N501Y in wild SARA-CoV-2 samples.
Figure: Identify N501Y mutations of SARS-CoV-2 variants.
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
Method: For ELISA, ADCP and ADCD assays, SARS-CoV-2 original and Beta variant full spike (L18F, D80A, D215G, K417N, E484K, N501Y, D614G, A701V, 242-244 del), RBD original and Beta (
Result: As for full spike (Figure S1), CR3022 ADCC against the RBD was unaffected by Beta RBD mutations (K417N, E484K, and N501Y), while ADCC mediated by P2B-2F6 was abrogated (Figure 3A).
Table: N501Y
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies.
PMID: 35380448
2022
Science translational medicine
Result: We compared the neutralization titers of these serum samples against pseudoviruses bearing spike proteins from the following variants: D614G, Omicron (A67V, del69-70, T95I, del142-144, Y145D, del211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R,
SARS_CoV_2 mutation literature information.
PMID: 
2022
Future microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT